# Investigate the Effect of AZD1656 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Type 2 Diabetes Mellitus (T2DM) Patients

> **NCT01103609** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 16 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Warfarin
- **DRUG:** Placebo
- **DRUG:** AZD1656

## Key facts

- **NCT ID:** NCT01103609
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2010-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01103609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01103609, "Investigate the Effect of AZD1656 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Type 2 Diabetes Mellitus (T2DM) Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01103609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*